Global Biciruizumab Market Strategic Research Report

Scope of the Report

The global Biciruizumab market size is predicted to grow from US$ 2,464 million in 2025 to US$ 8,853 million in 2032; it is expected to grow at a CAGR of 15.6% from 2026 to 2032.

Bevacizumab is a recombinant humanized monoclonal antibody primarily used for the treatment of various types of cancer, including colorectal cancer, non-small cell lung cancer, and renal cell carcinoma. It works by targeting and inhibiting the action of vascular endothelial growth factor (VEGF), preventing the formation of new blood vessels in tumors, thus reducing tumor blood supply and inhibiting tumor growth and spread. Bevacizumab is widely used in combination cancer therapies, typically in conjunction with chemotherapy or other targeted drugs to enhance therapeutic efficacy. The drug is administered intravenously and has been approved for clinical use in multiple countries and regions.In 2025, global Bimekizumab production reached approximately 1.2 million vials.

Bevacizumab holds an important position in the global cancer drug market, especially in the treatment of various solid tumors, such as colorectal cancer, non-small cell lung cancer, and renal cell carcinoma. With the continuous rise in cancer prevalence and ongoing innovations in cancer treatment, the market demand for Bevacizumab is steadily increasing. This drug works by inhibiting vascular endothelial growth factor (VEGF), blocking tumor angiogenesis, and significantly improving treatment outcomes, particularly when used in combination with chemotherapy and other targeted therapies. The market prospects for Bevacizumab are very promising, particularly in developing countries and emerging markets, where improvements in healthcare infrastructure and the widespread adoption of cancer screening will benefit more patients. Although Bevacizumab is priced relatively high and faces competition from generic drugs, it remains a core component of many cancer treatment regimens. Additionally, as research into Bevacizumab’s use in other cancer types continues to expand, it is expected that the drug’s indications will continue to grow, further driving market growth.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Biciruizumab market?

What factors are driving Biciruizumab market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Biciruizumab market opportunities vary by end market size?

How does Biciruizumab break out by Type, by Application?

This report presents a comprehensive overview of the global Biciruizumab market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 100 mg/4 mL
• 320 mg/2 mL

Segment by Specification

• Bimekizumab In Combination With Methotrexate
• Bimekizumab Combined With Topical Corticosteroids

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Dosage Form

• Intravenous Injection
• Subcutaneous Injection

Segment by Application

• Psoriasis
• Ankylosing Spondylitis
• Hidradenitis Suppurativa
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Biciruizumab market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Psoriasis, Ankylosing Spondylitis, Hidradenitis Suppurativa evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact